Based on the Shield Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Shield Therapeutics plc is not available over the next 12 months. Shield Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Shield Therapeutics plc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Shield Therapeutics plc’s stock price was GBX 2.40. Shield Therapeutics plc’s stock price has changed by -5.88% over the past week, -14.29% over the past month and +29.73% over the last year.
No recent analyst target price found for Shield Therapeutics plc
No recent average analyst rating found for Shield Therapeutics plc
Company Overview Shield Therapeutics plc
N/A
N/A
N/A
N/A
GBX
UK
Adjusted Closing Price for Shield Therapeutics plc (STX:LSE)
Loading...
Unadjusted Closing Price for Shield Therapeutics plc (STX:LSE)
Loading...
Share Trading Volume for Shield Therapeutics plc Shares
Loading...
Compare Performance of Shield Therapeutics plc Shares
Frequently Asked Questions About Shield Therapeutics plc (STX:LSE) Stock
Stock Target Advisor's fundamental analysis for Shield Therapeutics plc's stock is Very Bearish.
Unfortunately we do not have enough data on STX:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on STX:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on STX:LSE's stock to indicate if its overvalued.
The last closing price of STX:LSE's stock was GBX 2.40.
Unfortunately we do not currently have any market capitalization data for STX:LSE's stock.
Unfortunately we do not have enough analyst data on STX:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Shield Therapeutics plc's stock.
Sorry, we do not have any data on the number of employees for Shield Therapeutics plc.
Sorry we do not have any infomation available on Shield Therapeutics plc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Shield Therapeutics plc (STX:LSE) Stock
Stock Target Advisor's fundamental analysis for Shield Therapeutics plc's stock is Very Bearish.
Unfortunately we do not have enough data on STX:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on STX:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on STX:LSE's stock to indicate if its overvalued.
The last closing price of STX:LSE's stock was GBX 2.40.
Unfortunately we do not currently have any market capitalization data for STX:LSE's stock.
Unfortunately we do not have enough analyst data on STX:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Shield Therapeutics plc's stock.
Sorry, we do not have any data on the number of employees for Shield Therapeutics plc.
Sorry we do not have any infomation available on Shield Therapeutics plc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STX:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
